POLICY Document for Onpattro

The overall objective of this policy is to support the appropriate and cost effective use of the medication, lower cost site of care and overall clinically appropriate use. This document provides specific information to each section of the overall policy.

Section 1: Site of Care

Policy information specific to site of care (outpatient, hospital outpatient, home infusion)

Section 2: Clinical Criteria

• Policy information specific to the clinical appropriateness for the medication

Section 1: Site of Care

Site of Care Criteria Administration of Intravenous Onpattro

POLICY

I. CRITERIA FOR APPROVAL FOR ADMINISTRATION IN OUTPATIENT HOSPITAL SETTING

This policy provides coverage for administration of Onpattro in an outpatient hospital setting for up to 45 days when a member is new to therapy or is reinitiating therapy after not being on therapy for more than 6 months.

This policy provides coverage for administration of Onpattro in an outpatient hospital setting for a longer course of treatment when ANY of the following criteria are met:

- A. The member has experienced an adverse reaction to the drug that did not respond to conventional interventions (eg, acetaminophen, steroids, diphenhydramine, fluids, other pre-medications or slowing of infusion rate) or a severe adverse event (anaphylaxis, anaphylactoid reactions, myocardial infarction, thromboembolism, or seizures) during or immediately after an infusion.
- B. The member is medically unstable (eg respiratory, cardiovascular, or renal conditions).
- C. The member has severe venous access issues that require the use of special interventions only available in the outpatient hospital setting.
- D. The member has significant behavioral issues and/or physical or cognitive impairment that would impact the safety of the infusion therapy AND the patient does not have access to a caregiver.
- E. The member is less than 21 years of age or is 65 years of age or older.

For situations where administration of Onpattro does not meet the criteria for outpatient hospital infusion, coverage for Onpattro is provided when administered in alternative sites such as; physician office, home infusion or ambulatory care.

II. REQUIRED DOCUMENTATION

The following information is necessary to initiate the site of care prior authorization review (where applicable):

- A. Medical records supporting the member has experienced an adverse reaction that did not respond to conventional interventions or a severe adverse event during or immediately after an infusion
- B. Medical records supporting the member is medically unstable
- C. Medical records supporting the member has severe venous access issues that requires specialized interventions only available in the outpatient hospital setting

Onpattro_CareFirst_SOC_P2019 Onpattro 2659-A SGM P2019 SOC2019.docx

© 2019 CVS Caremark. All rights reserved.

This document contains confidential and proprietary information of CVS Caremark and cannot be reproduced, distributed or printed without written permission from CVS Caremark. This document contains prescription brand name drugs that are trademarks or registered trademarks of pharmaceutical manufacturers that are not affiliated with CVS Caremark.



D. Medical records supporting the member has behavioral issues and/or physical or cognitive impairment and no access to a caregiver

Section 2: Clinical Criteria

SPECIALTY GUIDELINE MANAGEMENT

ONPATTRO (patisiran)

POLICY

I. INDICATIONS

The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

FDA-Approved Indications

Onpattro is indicated for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.

All other indications are considered experimental/investigational and not medically necessary.

II. REQUIRED DOCUMENTATION

Submission of the following information is necessary to initiate the prior authorization review:

- A. Testing or analysis confirming a mutation of the TTR gene
- B. Medical record documentation confirming the member demonstrates signs and symptoms of polyneuropathy and an improvement in these signs and symptoms since starting therapy for continuation

III. PRESCRIBER SPECIALTIES

This medication must be prescribed by or in consultation with a neurologist, geneticist, or physician specializing in the treatment of amyloidosis.

IV. CRITERIA FOR INITIAL APPROVAL

Polyneuropathy of Hereditary Transthyretin-mediated Amyloidosis

Authorization of 12 months may be granted for treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis (also called transthyretin-type familial amyloid polyneuropathy [ATTR-FAP]) when all of the following criteria are met:

- A. The diagnosis is confirmed by detection of a mutation of the TTR gene.
- B. Member exhibits clinical manifestations of ATTR-FAP (e.g., amyloid deposition in biopsy specimens, TTR protein variants in serum, progressive peripheral sensory-motor polyneuropathy).
- C. The member is not a liver transplant recipient.
- D. The requested medication will not be used in combination with inotersen (Tegsedi) or tafamidis.

Onpattro_CareFirst_SOC_P2019 Onpattro 2659-A SGM P2019_SOC2019.docx

© 2019 CVS Caremark. All rights reserved.

This document contains confidential and proprietary information of CVS Caremark and cannot be reproduced, distributed or printed without written permission from CVS Caremark. This document contains prescription brand name drugs that are trademarks or registered trademarks of pharmaceutical manufacturers that are not affiliated with CVS Caremark.



V. CONTINUATION OF THERAPY

Authorization of 12 months may be granted for the continued treatment of ATTR-FAP when all of the following criteria are met:

- A. The member must have met all initial authorization criteria.
- B. The member must have demonstrated a beneficial response to treatment with Onpattro therapy compared to baseline (e.g., improvement of neuropathy severity and rate of disease progression as demonstrated by the modified Neuropathy Impairment Scale+7 (mNIS+7) composite score, the Norfolk Quality of Life-Diabetic Neuropathy (QoL-DN) total score, polyneuropathy disability (PND) score, FAP disease stage, manual grip strength). Documentation from the medical record must be provided.


REFERENCES:

SECTION 1

1. Onpattro [package insert]. San Diego, CA: Alnylam Pharmaceuticals, Inc..; August 2018.

SECTION 2

- 1. Onpattro [package insert]. Cambridge, MA: Alnylam Pharmaceuticals, Inc.; August 2018.
- 2. Adams, et al. Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis. N Engl J Med. 2018 Jul 5; 379(1):11-21.
- 3. Ando Y, Coelho T, Berk JL, Cruz MW, Ericzon BG, Ikeda S, Lewis WD, Obici L, Planté-Bordeneuve V, Rapezzi C, et al. Guideline of transthyretin-related hereditary amyloidosis for clinicians. Orphanet J Rare Dis. 2013; 8:31.
- Sekijima Y, Yoshida K, Tokuda T, Ikeda S. Familial transthyretin amyloidosis. In: GeneReviews. Seattle (WA): University of Washington, Seattle. 1993-2017. https://www.ncbi.nlm.nih.gov/books/NBK1194/. Accessed 16 Aug 2018.



 $\hbox{@\,}2019$ CVS Caremark. All rights reserved.

